1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Drugs In Development, 2022, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 23, 143, 123, 3, 7, 68, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 7, 2, 14 and 5 molecules, respectively.
Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Cervical Cancer - Overview
- Cervical Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cervical Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cervical Cancer - Companies Involved in Therapeutics Development
- Cervical Cancer - Drug Profiles
- Cervical Cancer - Dormant Projects
- Cervical Cancer - Discontinued Products
- Cervical Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Cervical Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Cervical Cancer - Dormant Projects, 2022
- Cervical Cancer - Discontinued Products, 2022
- Number of Products under Development for Cervical Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aadi Bioscience Inc
- AbbVie Inc
- Abivax SA
- Acrivon Therapeutics Inc
- ADC Therapeutics SA
- Advaxis Inc
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Aeterna Zentaris Inc
- Affimed GmbH
- Agenus Inc
- Akeso Inc
- Alkermes Plc
- Alligator Bioscience AB
- Almac Discovery Ltd
- Alphamab Oncology
- Alpine Immune Sciences Inc
- amcure GmbH
- Amgen Inc
- Aminex Therapeutics Inc
- Andes Biotechnologies
- Anteris Technologies Ltd
- AntiCancer Inc
- Apimeds Inc
- Apollomics Inc
- Arcus Biosciences Inc
- Ascendis Pharma AS
- Ascenta Therapeutics Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Aucentra Therapeutics Pty Ltd
- Bayer AG
- BeiGene Ltd
- Beijing Corregene Biotechnology Co Ltd
- Beijing Kangleweishi Biotechnology Co Ltd
- Beijing Neoantigen Biotechnology Co Ltd
- Beijing Weiyuan Likang Biological Technology Co Ltd
- Bio-Thera Solutions Ltd
- BioAtla Inc
- Biocad
- BioIntegrator
- Bioleaders Corp
- Biomics Biotechnologies Co Ltd
- BioNTech SE
- Biotheus Inc
- BioVaxys Technology Corp
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Cellestia Biotech AG
- Cellid Co Ltd
- Cellular Biomedicine Group Ltd
- Center for Genetic Engineering and Biotechnology
- Centrymed Pharmaceutical Inc
- Centus Biotherapeutics Ltd
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Institute of Biological Products Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chineo Med Beijing Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Clovis Oncology Inc
- Codiak BioSciences Inc
- Coherent Biopharma
- Corvus Pharmaceuticals Inc
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- Cue Biopharma Inc
- Cullinan Oncology Inc
- Curis Inc
- CytomX Therapeutics Inc
- CZ BioMed Corp
- DAE HWA Pharmaceutical Co Ltd
- Daewon Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Defence Therapeutics Inc
- Disulfican Ltd
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- DynamiCure Biotechnology LLC
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Enara Bio Ltd
- Enhancedbio Inc
- Epygen Biotech Pvt Ltd
- eTheRNA Immunotherapies NV
- Etna Biotech Srl
- Eubiologics Co Ltd
- Exelixis Inc
- EyeGene Inc
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Flow Pharma Inc
- Fujifilm Holdings Corp
- Fusion Pharmaceuticals Inc
- Gene Surgery
- Genentech USA Inc
- Genetic Immunity Inc
- Genexine Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genmab AS
- Gilead Sciences Inc
- GlycoNex Inc
- GlyTR Therapeutics Inc
- Gradalis Inc
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Sinogen Pharmaceutical Co Ltd
- Guangzhou Yinming Biomedical Technology Co Ltd
- Hamlet Pharma AB
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- Hefei Ruichengsheng Biotechnology Co Ltd
- HiFiBiO Therapeutics Inc
- Hookipa Pharma Inc
- Huabo Biopharm (Shanghai) Co Ltd
- Hummingbird Bioscience Pte Ltd
- Hutchison MediPharma Ltd
- ImCheck Therapeutics SAS
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunitor Inc
- ImmunityBio Inc
- Immuno Cure BioTech Ltd
- IMV Inc
- Incyte Corp
- Indaptus Therapeutics Inc
- Inhibrx Inc
- InnoMab Pte Ltd
- Innovative Cellular Therapeutics Co Ltd
- Innovene
- Innovent Biologics Inc
- Instil Bio Inc
- Invectys SA
- Iovance Biotherapeutics Inc
- ISA Pharmaceuticals BV
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Recbio Technology Co Ltd
- Joint Biosciences Ltd
- Karyopharm Therapeutics Inc
- Kidswell Bio Corp
- Kintara Therapeutics Inc
- Komipharm International Co Ltd
- Kortuc Inc
- Kymab Ltd
- Laekna Therapeutics Shanghai Co Ltd
- LightOx Ltd
- MacroGenics Inc
- MaxiVAX SA
- MedGene Therapeutics Inc
- Medical Guidance Systems LLC
- Medicenna Therapeutics Corp
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- MicroQuin Ltd
- Midissia Therapeutics Inc
- Molecular Partners AG
- Morphogenesis Inc
- Multitude therapeutics Inc
- Mundipharma EDO GmbH
- Mycenax Biotech Inc
- Nanobiotix SA
- Nanocan Therapeutics Corp
- NanoMab Technology Ltd
- Nektar Therapeutics
- NeoTX Therapeutics Ltd
- Netris Pharma SAS
- Newish Technology Beijing Co Ltd
- NextCure Inc
- NGM Biopharmaceuticals Inc
- Novartis AG
- Novita Pharmaceuticals Inc
- Nurix Therapeutics Inc
- Nuvectis Pharma Inc
- Nykode Therapeutics ASA
- Obsidian Therapeutics Inc
- Ocellaris Pharma Inc
- Ology Bioservices Inc
- Onconova Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- Orgenesis Inc
- Origincell Technology Group Co Ltd
- Oxford Vacmedix UK Ltd
- PDS Biotechnology Corp
- Pfizer Inc
- Pharma Mar SA
- PharmAbcine Inc
- Philogen SpA
- Phoenix Life Sciences International Ltd
- PI Therapeutics Ltd
- Pionyr Immunotherapeutics Inc
- Plus Therapeutics Inc
- Precigen Inc
- Precision Biologics Inc
- Prelude Therapeutics Inc
- Prestige BioPharma Ltd
- Privo Technologies Inc
- PsiOxus Therapeutics Ltd
- Puma Biotechnology Inc
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Qingdao Sino-Cell Biomedicine Co Ltd
- Quadriga BioSciences Inc
- Qurient Co Ltd
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Relay Therapeutics Inc
- RemeGen Co Ltd
- Repertoire Immune Medicines Inc
- Rizen (Suzhou) Biosciences Co Ltd
- Rubius Therapeutics Inc
- Salarius Pharmaceuticals Inc
- Samyang Biopharmaceuticals Corp
- Sanofi
- Savoy Pharmaceuticals Inc
- SCG Cell Therapy Pte Ltd
- Seagen Inc
- Sentan Pharma Inc
- Seven and Eight Biopharmaceuticals Corp
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Gencells Therapeutics Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Jiatan Pharmaceutical Technology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yihao Biotechnology Co Ltd
- Shanghai Yuansong Biotechnology Co Ltd
- Shanghai Zerun Biotechnology Co Ltd
- Shantha Biotechnics Pvt Ltd
- Shattuck Labs Inc
- Sichuan Kelun Pharmaceutical Co Ltd
- Simcha Therapeutics Inc
- Sino Biopharmaceutical Ltd
- SinoCelltech Group Ltd
- Sirnaomics Ltd
- SK Bioscience Ltd
- Sorrento Therapeutics Inc
- SOTIO Biotech AS
- SQZ Biotechnologies Co
- Statera Biopharma Inc
- Sumitomo Pharma Co Ltd
- Shenghe (China) Biopharmaceutical Co Ltd
- Suzhou BlueHorse Therapeutics Co Ltd
- Suzhou Maximum Bio-tech Co Ltd
- Suzhou Stainwei Biotech Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Symphogen A/S
- Synermore Biologics Co Ltd
- Synthekine Inc
- Systimmune Inc
- T-Cure Bioscience Inc
- Taiho Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- TargImmune Therapeutics AG
- Tavotek Biotherapeutics
- TCR Cure Biopharma Technology Co Ltd
- Tevogen Bio Inc
- Theravectys SA
- Transcenta Holding Ltd
- Transgene SA
- Treadwell Therapeutics Inc
- TScan Therapeutics Inc
- Turnstone Biologics Inc
- Up Therapeutics Inc
- UTC Therapeutics Inc
- Vaccitech Plc
- Vascular Biogenics Ltd
- Vectorite Biomedical Inc
- Verastem Inc
- Veru Inc
- ViciniVax BV
- Vincerx Pharma Inc
- Vir Biotechnology Inc
- Virion Therapeutics LLC
- Virometix AG
- VLP The Vaccines Company SL
- VM Discovery Inc
- Voltron Therapeutics Inc
- West Lake Biomedical Technology (Hangzhou) Co Ltd
- Wuhan Binhui Biotechnology Co Ltd
- Xencor Inc
- Xiamen Innovax Biotech Co Ltd
- Y-Biologics Inc
- Zai Lab Ltd
- Zeria Pharmaceutical Co Ltd
- Zhejiang Yangshengtang Biotech Co Ltd
- Zymeworks Inc
